Exact Sciences backs CMS policy update to waive cost-sharing for follow-up colonoscopy

Exact Sciences announced its support for recent policy changes that aim to increase access to noninvasive colorectal cancer screening tests and require Medicare and most insurers to pay for colonoscopy after a positive stool-based test.The company, which manufactures the stool-based DNA and hemoglobin screening test Cologuard, joined other industry partners and the AGA, the American Cancer Society Cancer Action Network and Fight Colorectal Cancer to advocate for policy updates and eliminate out-of-pocket cost barriers to CRC screening.According to an Exact Sciences press release, the recentRead More